Citius Pharmaceuticals (CTXR) Other Non-Current Liabilities (2014 - 2017)
Citius Pharmaceuticals' (CTXR) quarterly Other Non-Current Liabilities came in at $581164.0 in Q2 2017, down 80.28% YoY from $2.9 million in Q2 2016, and up 36.34% on a QoQ basis from $426264.0 in Q1 2017.
Citius Pharmaceuticals (CTXR) Other Non-Current Liabilities (2014 - 2017) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 4 years of Other Non-Current Liabilities data on file, last reported at $581164.0 in Q2 2017.
- Quarterly Other Non-Current Liabilities fell 80.28% year-over-year to $581164.0 in Q2 2017, while the trailing twelve-month figure through Jun 2017 was $581164.0 (down 80.28% YoY) and the FY2016 annual result came in at $1.7 million, up 127.62% from the prior year.
- Other Non-Current Liabilities advanced to $581164.0 in Q2 2017, from $426264.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $2.9 million in Q2 2016 to a low of $426264.0 in Q1 2017.
- A 4-year average of $1.3 million and a median of $1.2 million in 2015 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2016 — Other Non-Current Liabilities surged 127.62% — and 2017, when it slumped 80.28%.
- Tracing CTXR's Other Non-Current Liabilities over 4 years: stood at $1.4 million in 2014, then sank by 37.21% to $872999.0 in 2015, then gained by 4.3% to $910578.0 in 2016, then sank by 36.18% to $581164.0 in 2017.
- The last three Other Non-Current Liabilities figures came in at $581164.0 (Q2 2017), $426264.0 (Q1 2017), and $910578.0 (Q4 2016), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Citius Pharmaceuticals | 15.71 Mn | 15.71 Mn | 1.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2017 | 581,164.00 |
| Mar 31, 2017 | 426,264.00 |
| Dec 31, 2016 | 910,578.00 |
| Sep 30, 2016 | 1.68 Mn |
| Jun 30, 2016 | 2.95 Mn |
| Dec 31, 2015 | 872,999.00 |
| Sep 30, 2015 | 738,955.00 |
| Jun 30, 2015 | 1.72 Mn |
| Mar 31, 2015 | 1.25 Mn |
| Dec 31, 2014 | 1.39 Mn |
| Sep 30, 2014 | 1.45 Mn |